ISPOR Lifetime Achievement Awards

ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award

Avedis Donabedian Award Chair
Sean Sullivan, PhD, Stergachis Family Professor and Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

Background: The ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award is established in honor of the late Avedis Donabedian MD, MPH to acknowledge those individuals who have made a major contribution to the improvement of health outcomes. Dr. Donabedian was a renowned faculty member of the University of Michigan School of Public Health, multiple Award-winner, author of eight books, more than 50 peer-reviewed articles, and countless lectures on the subject of outcomes research. He dedicated his life to improving the quality of health care and health care systems, and directed such research towards health outcomes as the measure of quality. He has been called the “Father of Outcomes Research”.

Description: The ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award is international in scope and stature. The Award recognizes an individual’s outstanding, life-long achievement in the area of improving health outcomes. It will be presented on a frequency determined by the ISPOR Lifetime Achievement Awards Committee, but not more than one time per year.

Criteria: The Award is open to any person who through his or her life’s endeavors has demonstrated a significant and lasting contribution towards better health outcomes in a population or sub-population, as defined by the Lifetime Achievement Awards Committee. The Award is targeted towards demonstrated value delivered in health outcomes, rather than purely academic achievement. Therefore, nominees will be expected to have demonstrated tangible and persistent contributions that led towards improved health outcomes in an identifiable group of individuals. Academicians, industry professionals, economists, researchers and others who meet these criteria are eligible, including ISPOR members. Self-nominations are discouraged. Deceased persons are not eligible for the Award. However, should the recipient die prior to receiving the Award, it may be presented posthumously.

Nomination Process: The Call for Nominations will be advertised in the ISPOR CONNECTIONS, on the ISPOR website, and any other appropriate journal/newsletter. Anyone who meets the criteria above may be nominated. Nominations may be made by any ISPOR member. Members may nominate more than one person; however a completed letter of recommendation must accompany each nomination. Nominators are responsible for ensuring that all necessary documentation is forwarded with their submission.

Selection Process: The Lifetime Achievement Awards Committee selects the recipient by reviewing the materials submitted for each nominee and determining the overall impact of his or her contributions towards improving health outcomes. The Donabedian Award is targeted towards demonstrated value delivered in health outcomes rather than purely academic achievement. The Committee will then recommend the recipient of the Award to the Board of Directors.

ISPOR members may nominate more than one person. All nominations must include:

a brief essay indicating the reason for your nomination
the nominee’s curriculum vitae
supporting documentation including publication citations and any other notable achievements of the nominee in the area of outcomes research.

ISPOR members will be asked to volunteer for the Lifetime Achievement Award Committee (LAAC). The ISPOR Awards Committee Chair will select a Chair for the LAAC. The LAAC will select several volunteers for the LAAC Core Group.

After all nominations have been received, the Chair of the LAAC will prepare a brief description of each nominee and will send it to the LAAC.

The LAAC will provide a commentary and a ranking for each nominee.

Using the results of the ranking, the Chair and the LAAC selects the recipient.

The selected recipient, along with supporting documentation, and a list of the other top ranking nominees, with documentation, will be sent to the Board of Directors for approval of the selected candidate.

Nature of the Award: The Award will be announced and presented to the chosen individual at either the ISPOR International Meeting or the ISPOR European Congress, as appropriate. The Award recipient will receive a complimentary registration and travel expenses to the next ISPOR Annual International Meeting or ISPOR European Congress that convenes immediately following the Award selection process. The recipient will also have the opportunity to address the general assembly at either of these meetings, or alternatively address the membership of ISPOR through a commentary in Value in Health.

Nominations for the Avedis Donabedian Outcomes Research Lifetime Achievement Award require a letter of support for the nominee and a current edition of the nominee's CV, and sent to: awards@ispor.org.

Josephine Mauskopf, PhD, MHA
Vice President, Health Economics at RTI‑HS

Josephine Mauskopf, PhD, MHA, is Vice President of Health Economics at RTI‑HS. She has worked in several areas of health economics including health benefits assessment for toxic substance or food safety regulations and economic evaluations of new health care interventions. Examples of her work in each of these areas include: estimation of the health benefits from banning several asbestos containing products; estimation of the QALYs lost from every foodborne illness and use of these estimates for cost utility analyses for determining the value of food safety regulations; development of methodological guidance for budget impact and population outcomes analyses for new health care interventions. Dr. Mauskopf completed an 8-year term as Editor-in-Chief of the journal Value in Health. She served for 4 years as a reviewer on the Health Care Technology and Decision Sciences Study Section at the Agency for Healthcare Research and Quality. She has presented her research at numerous national and international symposia and is an author on many peer-reviewed publications.

Donald Patrick, PhD, MSPH
Director, University of Washington, Seattle, WA, USA

Professor Donald Patrick, PhD, MSPH, has worked on outcomes for over 45 years. He is Professor of Health Services at the University of Washington with appointments in Epidemiology, Pharmacy, Rehabilitation Medicine, and Sociology and is a Full Member of the Fred Hutchinson Cancer Research Center. Dr. Patrick is internationally recognized as a leading developer and user of multiple generic and disease-specific measures; he directs the Seattle Quality of Life Group (www.seaqolgroup.org) and works on projects funded by the National Institutes of Health, AHRQ, and Industry. Dr. Patrick is active in research on service systems, health disparities in cancer populations, children and adolescents, and people with disabilities. Dr. Patrick is a member of the Institute of Medicine, and as a Special Government Employee, he contributed to the FDA Guidance on Patient-Reported Outcome Measures for Use in Medical Product Development and Labeling Claims. Dr. Patrick is a member of the Board of Directors of ISPOR and participates actively in Task Forces and other work. He is author of numerous articles and monographs, a classic book written with Pennifer Erickson entitled, Health Status and Health Policy and a book with Richard Deyo entitled, Hope or Hype: The Obsession with Medical Advance and the High Cost of False Promises.

Sir Michael Rawlins, MD, FMedSci
Chairman, National Institute of Health & Clinical Excellence (NICE), London, UK

Sir Michael Rawlins, has been chairman of the National Institute of Health & Clinical Excellence (NICE) since its formation in 1999. He is also chairman of the Advisory Council on the Misuse of Drugs (since 1998). He is an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne. He was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at the University of Newcastle upon Tyne from 1973 to 2006. At the same time he held the position of Consultant Physician and Consultant Clinical Pharmacologist to the Newcastle Hospitals NHS Trust. He was Vice Chairman (1987-1992) and Chairman (1993-1998) of the Committee on Safety of Medicines.

Martin J. Buxton
Professor of Health Economics and Director of the Health Economics Research Group

Martin Buxton is Professor of Health Economics at Brunel University and, until he stepped down in January 2010, was for many years the Director of Brunel’s Health Economics Research Group (HERG) which he built up into a leading academic centre for applied health economics. He has supervised as PhD students, trained as junior researchers or mentored as colleagues many health economists who are now leading researchers in the field. He has been actively involved in research on the economics of health and medical care for over thirty-five years, and has published (too) many papers. He has a particular interest in trying to undertake useful evaluations of health care interventions in situations where formal experimental data cannot be collected. More generally he has been concerned to help industry and other sponsors of technology provide robust economic evidence and the public sector to use that evidence appropriately in public policy-making. He has been actively involved with the UK National Institute for Health and Clinical Excellence in a number of roles, is currently a member of the UK National Screening Committee, and has acted as a consultant to most leading pharmaceutical companies.

Milton C. Weinstein, Ph.D.
Professor Health Policy & Management
Harvard School of Public Health, Boston, MA

Milton C. Weinstein, Ph.D., is the Henry J. Kaiser Professor of Health Policy and Management at the Harvard School of Public Health and Professor of Medicine at the Harvard Medical School. At the Harvard School of Public Health he is Academic Director of the Program in Health Decision Science, and Director of the Program on Economic Evaluation of Medical Technology. He is currently also Visiting Professor in the Department of Economics and Visiting Scholar in The Dartmouth Institute for Health Policy and Clinical Practice.

He is best known for his research on cost-effectiveness of medical practices and for developing methods of economic evaluation and decision analysis in health care. He is a co-developer of the CEPAC (Cost-Effectiveness of Preventing AIDS Complications) computer simulation model, and has conducted studies on prevention and treatment of HIV infections. He is the co-developer of the Coronary Heart Disease Policy Model, which has been used to evaluate the cost-effectiveness of cardiovascular prevention and treatment. He is an author of four books: Decision Making in Health and Medicine: Integrating Evidence and Values; Cost-Effectiveness in Health and Medicine, the report of the Panel of Cost Effectiveness in Health and Medicine; Clinical Decision Analysis; and Hypertension: A Policy Perspective. He has also published more than 200 papers in peer-reviewed medical, public health, and economics journals.

He consults with industry and government and is a Principal Consultant with i3 Innovus. He is an elected member of the Institute of Medicine of the National Academy of Sciences, and a recipient of the Award for Career Achievement from the Society for Medical Decision Making. Dr. Weinstein received his A.B. and A.M. in Applied Mathematics (1970), his M.P.P. (1972), and his Ph.D. in Public Policy (1973) from Harvard University.

Bryan R. Luce, PhD, MBA
Senior Vice President Science Policy for United BioSource Corporation

Bryan R. Luce, PhD, MBA is Senior Vice President, Science Policy, for United BioSource Corporation. Dr. Luce founded The MEDTAP® International, serving as its Chairman, President and CEO until 2002. Previously, he held positions as Director of Battelle’s Centers for Public Health Research and Evaluation, Director of the Office of Research and Demonstrations, Centers for Medicare and Medicaid Services and Senior Analyst, Office of Technology Assessment (OTA) of the United States Congress.

Dr. Luce is a consultant to numerous government agencies as well as pharmaceutical and device firms worldwide, a member or chair of socioeconomic and public health policy advisory boards for several leading pharmaceutical companies, and recently was a member of the Medicare Evidence Development & Coverage Advisory Committee (MedCAC). He holds academic appoints as Senior Scholar with the Department of Health Policy, Jefferson Medical College and Adjunct Senior Fellow of the Leonard Davis Institute, University of Pennsylvania. In addition, Dr. Luce is on the editorial boards of several leading health journals, including Value in Health and the American Journal of Managed Care. He has authored more than eighty scientific publications, including three textbooks on technology assessment, health policy, and cost-effectiveness analysis. Dr. Luce founded and chairs the Bayesian Initiative in Health Economics and Outcomes Research. He is a Past President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and is a Lieutenant Colonel (Retired), Medical Service Corps, US Army Reserves. Dr. Luce’s undergraduate and masters training were at the Universities of Vermont and Massachusetts at Amherst. He received his Doctorate from the School of Public Health at the University of California at Los Angeles (UCLA).

David Eddy MS, PhD
Archimedes, Inc.

David Eddy is a physician-mathematician living in Aspen, Colorado. Starting more than 30 years ago he has done seminal work in guidelines, mathematical modeling, cost-effectiveness, coverage decisions, medical necessity and performance measurement.

He is one of the founders of the “evidence-based” movement, promoting and teaching the application of evidence to guidelines, coverage policies, performance measures and medical necessity. The author of five books and more than 100 first-authored articles, including a series of essays for the Journal of the American Medical Association, his writings span from technical mathematical theories to broad health policy topics. He has received 8 national and international awards in several different fields, including applied mathematics, health technology assessment, health care quality, and outcomes research.

He has been elected or appointed to more than forty national and international boards and commissions -- including Consumers Union, the National Board of Mathematics, the World Health Organization Panel of Experts, The Blue Cross Blue Shield Medical Advisory Panel, and the National Committee for Quality Assurance – and is a member of the Institute of Medicine/National Academy of Sciences. He was Professor of Engineering and Medicine at Stanford, and then the J. Alexander McMahon Professor of Health Policy and Management at Duke University, before he resigned to become an independent researcher and writer. He is the founder and co-inventor of the Archimedes model, and is currently the Medical Director of Archimedes, Inc.

George W. Torrance, PhD
Professor Emeritus at McMaster University, Canada
Principal Consultant for i3 Innovus

Dr. Torrance is Professor Emeritus at McMaster University, Canada, and Principal Consultant for i3 Innovus, a global leader in health economics, outcomes and data analysis. He has been a leading researcher, teacher and practitioner in the field of health economics and outcomes research for over three decades.

As a methodologist, Dr. Torrance pioneered many of the methods used today in health economics, particularly the use of utility theory to measure preferences for health outcomes, and the concept of quality-adjusted life years and their use in cost-utility analyses. In addition he and his colleagues developed the widely applied Health Utilities Index.
As a teacher, Dr. Torrance has trained generations of researchers and practitioners through courses, workshops, journal articles, textbooks including the ISPOR Book of Terms, and through mentorship of junior and senior colleagues and students.

As a practitioner, the results of studies conducted by Dr. Torrance have laid a foundation for evidence-based medicine and health policy and contributed to a more efficient allocation of resources in healthcare. Dr. Torrance is truly one of the pioneers in our field.

Kathleen N. Lohr PhD

Kathleen Lohr, PhD, appointed as an RTI Distinguished Fellow in June 2003, has more than 30 years of experience in the field of health outcomes and health services research. She joined RTI in 1996, serving as senior program director for the health services and policy research program. Among Dr. Lohr's scientific contributions to RTI and her field has been strengthening bridges between RTI and the University of North Carolina at Chapel Hill where she holds the rank of Research Professor. The most striking example of her efforts in this area is the RTI-UNC Evidence-based Practice Center, for which she is the principal investigator. Her work in evidence-based practice builds on an international reputation in quality of care, clinical practice guidelines, and quality of life measurement. She has published 51 monographs and research reports, 17 book chapters, and over 100 peer-reviewed articles.

Michael F. Drummond, PhD
Professor of Economics and Director of the Centre for Health Economics
University of York, UK

Michael Drummond is Professor of Economics and Director of the Centre for Health economics at the University of York, UK. He obtained his PhD from York in 1983, having previously obtained degrees in engineering and business administration.

His main research interest is in the economic evaluation of health care programmes and he has undertaken a wide range of empirical studies. In addition, he has written numerous ethodological papers and co-authored one of the main textbooks in the field.

In addition to his academic work, he has acted as consultant to the WHO and participated in numerous projects for the European Union. He is also Vice-President (European Operations) for Innovus, a contract research organization. He has served on numerous government committees in the UK, including the Medicines Commission and the National Institute for Clinical Excellence (NICE) Guidelines Advisory Committee.

John E. Ware, Jr. PhD
Chief Executive Officer, Chief Science Officer and Chairman of the Board
QualityMetric Incorporated

Dr. Ware founded QualityMetric Incorporated, in 1997 and serves as its Chief Executive Officer, Chief Science Officer, and Chairman of the Board. For nearly 15 years he has maintained academic affiliations with the Health Assessment Lab in Boston and faculty appointments as Research Professor in the Department of Medicine at Tufts University School of Medicine and Adjunct Professor in the School of Public Health at Harvard University. He is a member of the Institute of Medicine (IOM), National Academy of Sciences.

Prior to founding QualityMetric, Dr. Ware served for 12 years as Senior Scientist, The Health Institute, Tufts New England Medical Center in Boston, and served as the Principal Investigator for the Medical Outcomes Study (MOS), where he developed the SF-36® Health Survey and other tools widely used in monitoring patient outcomes. Prior to moving to Boston in 1988, he was Senior Research Psychologist for 14 years at the RAND Corporation where he developed the health status and patient satisfaction measures used in the Health Insurance Experiment. His hundreds of publication credits include papers from the MOS, which received the Association for Health Service Research (ASHR) “Article of the Year” Award for 1993.

In addition to his election to the IOM, Dr. Ware’s awards and honors include Pepperdine University’s 25th Annual Dolores Award to the outstanding graduate in psychology and education, AHSR’s 1994 “Distinguished Investigator” Award, the 1998 Novartis/Zitter Group “Outcomes Leadership Award” for his work in advancing the science of outcomes research, and in 1999, he was the individual recipient of the Ellwood Award presented by the Foundation for Accountability (FACCT), in recognition of his lifetime efforts and contribution to the creation “of a consumer-focused, accountable health care system”.